Zobrazeno 1 - 10
of 377
pro vyhledávání: '"Sang Gyune, Kim"'
Autor:
Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 3, Pp 388-405 (2024)
Background/Aims Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified qSOFA (m-qSOFA) to identify high-risk patients
Externí odkaz:
https://doaj.org/article/23460ebdd79b41698a5129f5b959af23
Autor:
Jeong-Ju Yoo, Sun Ah Maeng, Young Chang, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Gab Jin Cheon, Young Seok Kim, Hong Soo Kim, Sang Gyune Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Managing complications of liver cirrhosis such as varices needing treatment (VNT) and clinically significant portal hypertension (CSPH) demands precise and non-invasive diagnostic methods. This study assesses the efficacy of spleen stiffness
Externí odkaz:
https://doaj.org/article/7abdb348a4f8424bb4aede7fcb466542
Publikováno v:
Liver Cancer, Pp 1-11 (2024)
Introduction: The combination of atezolizumab/bevacizumab has emerged as an effective first-line treatment for advanced hepatocellular carcinoma (HCC). However, this therapy is potentially associated with bleeding complications, warranting a comprehe
Externí odkaz:
https://doaj.org/article/e421a5e6c3674506bd9814db22e3d35c
Publikováno v:
The Ewha Medical Journal, Vol 47, Iss 4 (2024)
Hepatocellular carcinoma (HCC) remains a critical health concern in Korea, ranking as the second leading cause of cancer mortality and imposing substantial economic burdens, particularly among the working-age population. This review examines recen
Externí odkaz:
https://doaj.org/article/9d1af3e064854f6fb111b546be7eb1aa
Autor:
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss Suppl, Pp S5-S105 (2024)
Externí odkaz:
https://doaj.org/article/ae865a09c31d418aad0e6ad255dcf119
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 9, Pp n/a-n/a (2024)
Abstract Introduction Among many antiretroviral drugs, tenofovir alafenamide is used extensively in combination regimens of tenofovir/emtricitabine or tenofovir/emtricitabine/bictegravir. However, concerns have arisen about the potential of tenofovir
Externí odkaz:
https://doaj.org/article/43a8b5f83d474ba6a70e69274423c7f9
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
ObjectivesSmoking is a preventable risk factor for morbidity and mortality in patients with liver disease. This study aims to explore the additional risks of smoking in the development of alcoholic liver disease (ALD), cirrhosis, and hepatocellular c
Externí odkaz:
https://doaj.org/article/edb79ce4fe444f528bea46d276b653a9
Publikováno v:
Journal of Liver Cancer, Vol 24, Iss 1, Pp 9-16 (2024)
Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredicta
Externí odkaz:
https://doaj.org/article/ef3aafeedcf84e5aa05a4d489d7ee5ff
Publikováno v:
Medicina, Vol 60, Iss 10, p 1634 (2024)
Background and Objectives: Immune checkpoint inhibitors (ICIs), which target immune checkpoints in cancer cells, are increasingly used as a mainstay in anticancer treatment. The combination of atezolizumab and bevacizumab is also a first-line treatme
Externí odkaz:
https://doaj.org/article/f21fb568a9b2415a9a4797b53562df1f
Autor:
Hyuk Kim, Yoon E Shin, Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Publikováno v:
Medicina, Vol 60, Iss 9, p 1422 (2024)
Background and Objectives: Immune check inhibitor (ICI) colitis is one of most common and adverse side effects of ICI. However, there was no case report of ulcerative colitis (UC)-mimicking colitis after atezolizumab use in hepatocellular carcinoma (
Externí odkaz:
https://doaj.org/article/f2996976b20d43e88aa2053691752a9c